Health Catalyst Inc(HCAT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.68 | Insider Own | 21.79% | Shs Outstand | 74.6M | Perf Week | -4.68% |
| Market Cap | 0.12B | Forward P/E | 201.73 | EPS next Y | 122.45% | Insider Trans | 0.36% | Shs Float | 58.9M | Perf Month | -6.32% |
| Enterprise Value | 0.19B | PEG | - | EPS next Q | -0.05 | Inst Own | 61.97% | Short Float | 3.76% | Perf Quarter | -23.83% |
| Income | -0.26B | P/S | 0.42 | EPS this Y | -119.99% | Inst Trans | -9.17% | Short Ratio | 3.72 | Perf Half Y | 18.98% |
| Sales | 0.29B | P/B | 1.21 | EPS next 5Y | -10.28% | ROA | -54.33% | Short Interest | 2.21M | Perf YTD | -31.8% |
| Book/sh | 1.35 | P/C | 1.19 | EPS past 3/5Y | 1.04% 2.63% | ROE | -118.12% | 52W High | -54.91% ($3.62) | Perf Year | -49.69% |
| Cash/sh | 1.37 | P/FCF | 15.49 | Sales past 3/5Y | 4.05% 10.5% | ROIC | -99.75% | 52W Low | 70.66% ($0.96) | Perf 3Y | -75.96% |
| Dividend Est. | - | EV/EBITDA | 12.04 | EPS Y/Y TTM | -143.41% | Gross Margin | 34.54% | Volatility(W/M) | 3.49% 4.26% | Perf 5Y | -96.83% |
| Dividend TTM | - | EV/Sales | 0.65 | Sales Y/Y TTM | -7.54% | Oper. Margin | -11.25% | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.68 | EPS Q/Q | 6.88% | Profit Margin | -90.61% | RSI (14) | 37.52 | Recom | 2.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.68 | Sales Q/Q | -12.68% | SMA20 | -6.2% ($1.74) | Beta | 1.53 | Target Price | $1.77 |
| Payout | - | Debt/Eq | 1.69 | Earnings | 2026/11/5 | SMA50 | -5% ($1.72) | Rel Volume | 0.33 | Prev Close | $1.69 |
| Employees | 1200 | LT Debt/Eq | 1.63 | EPS/Sales Surpr. | 33.78% 2.02% | SMA200 | -5.72% ($1.73) | Avg Volume(3M) | 0.60M | Price | $1.63 |
| IPO | 2019/7/25 | Option/Short | Yes/Yes | Trades | 1826 | Volume | 197,869 | Change | -3.55% |
Health Catalyst is a US company that provides a data and analytics platform for hospitals and health systems. It integrates scattered clinical, financial, and operational data into a single analytics environment and supplies hospitals with software and professional services to help improve performance. Founded and headquartered in Utah, the company has expanded its presence in the hospital data analytics market since going public.
Over the past 1 year, roughly in the middle
55% below its 1-year high.
Traded less than usual. That is 33% of its average volume.
Next earnings report: November 5
9 days to go.
HCAT has a sound balance sheet but weak earning power
Of every $100 in sales, $11.25 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -120.0% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $42. Peers typically go for $70.
Tap to view numbers
Results came in about as expected
Slight tendency to miss estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 62.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #28 of 41 in the industry
Based on market cap of $123M.
SY#26 So-Young International Inc ADR $180M PER - 
OPRX#27 OptimizeRx Corp $171M PER 38.6 HCAT#28 Health Catalyst Inc $123M PER - 
DH#29 Definitive Healthcare Corp $115M PER - 
LFMD#30 LifeMD Inc $100M PER - 
FAQ
What kind of company is HCAT?
HCAT belongs to the Healthcare sector and operates in the Health Information Services industry.
What is the market cap of HCAT?
The market cap of HCAT is approximately $123M, ranking 4,363 within its sector.
What is the 52-week high and low for HCAT?
HCAT has recorded a 52-week high of $3.62 and a low of $0.96.
